Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides
申请人:LEK Pharmaceuticals d.d.
公开号:EP2947077A1
公开(公告)日:2015-11-25
The invention belongs to the fields of pharmaceutical industry, and particularly to an improved stereoselective synthesis of intermediate compounds for the preparation of gliflozins, for example canagliflozin or structurally similar gliflozins. Gliflozins, such as canagliflozin, dapagliflozin, empagliflozin, or ipragliflozin, inhibit the sodium-dependent glucose cotransporter 2 (SGLT2) in the kidney and as such are useful in the treatment of type-2 diabetes.
该发明属于制药工业领域,特别涉及一种改进的立体选择性合成中间化合物的方法,用于制备格列酮糖类药物,例如卡格列净或结构类似的格列酮糖类药物。格列酮糖类药物,例如卡格列净、达格列净、恩帕格列净或伊普格列净,通过抑制肾脏中的钠依赖性葡萄糖共转运体2(SGLT2)而有助于治疗2型糖尿病。